US2003191149A1PendingUtilityA1
Compounds for treating fibromyalgia and chronic fatigue syndrome
Priority: Apr 21, 2000Filed: Mar 7, 2003Published: Oct 9, 2003
Est. expiryApr 21, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 21/00A61K 31/445A61K 31/48A61K 31/451A61K 31/4745
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds, substituted phenylazacycloalkane-type compounds, or cabergoline-type compounds, or a salt of any said compound.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating the symptoms of fibromyalgia syndrome or chronic fatigue syndrome, comprising administering to a patient in need of treatment a therapeutically effective amount of an active agent selected from the group consisting of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound, and a cabergoline-type compound, and pharmaceutically acceptable salts of any said compound.
2 . The method of claim 1 wherein said active agent is a heterocyclic amine-type compound of formula (A),
or a pharmaceutically acceptable salt thereof, wherein:
R 1 , R 2 , and R 3 are independently hydrogen, C 1-6 alkyl, C 3-5 alkenyl, C 3-5 alkynyl, C 3-7 cycloalkyl, C 4-10 cycloalkyl- or phenyl- substituted C 1-6 alkyl, or R 1 and R 2 are joined to form a C 3-7 cyclic amine which can contain additional heteroatoms and/or unsaturation;
X is hydrogen, C 1-6 alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl;
A is CH, CH 2 , CH-halogen, CHCH 3 , C═O, C═S, C—SCH 3 , C═NH, C—NH 2 , C—NHCH 3 , C—NHCOOCH 3 , C—NHCN, SO 2 , or N;
B is CH 2 , CH, CH-halogen, C═O, N, NH or N—CH 3 or O;
n is 0 or 1; and
D is CH, CH 2 , CH-halogen, C═O, O, N, NH, or N—CH 3 .
3 . The method of claim 2 wherein, in said formula (A), D is N or NH, and n is 0.
4 . The method of claim 2 wherein, in said formula (A), A is CH, CH 2 , CHCH 3 , C═O, C═S, C—SCH 3 , C═NH, C—NH 2 , C—NHCH 3 , C 13 NHCOOCH 3 , or C—NHCN.
5 . The method of claim 2 wherein, in said formula (A), A is CH or C═O.
6 . The method of claim 2 wherein said compound of formula (A) is a compound of formula (Aa):
7 . The method of claim 2 wherein said compound of formula (A) is (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]-quinolin-2(1H)-one (uninverted CAS name) or (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Generated by ACD/Name software).
8 . The method of claim 2 wherein said compound of formula (A) is a compound of formula (Ab):
9 . The method of claim 2 wherein said compound of formula (A) is (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]-quinolin-2(1H)one (Z)-2-butenedioate (1:1).
10 . The method of claim 2 wherein said compound of formula (A) is a compound of formula (Ac), or formula (VIII):
11 . The method of claim 2 wherein said compound of formula (A) is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione.
12 . The method of claim 2 wherein said compound of formula (A) is a compound of formula (Ad), or formula (IX):
13 . The method of claim 2 wherein said compound of formula (A) is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione maleate.
14 . The method of claim 1 wherein said active agent is a substituted phenylazacycloalkane-type compound of formula (B),
or a pharmaceutically acceptable salt thereof, wherein:
n is 0-3;
R 1 and R 2 are independently H (provided only one is H at the same time), —OH (provided R 4 is other than hydrogen), CN, CH 2 CN, 2- or 4-CF 3 , CH 2 CF 3 , CH 2 CHF 2 , CH═CF 2 , (CH 2 ) 2 CF 3 , ethenyl, 2-propenyl, OSO 2 CH 3 , OSO 2 CF 3 , SSO 2 CF 3 , COR 4 , COOR 4 , CON(R 4 ) 2 , SO x CH 3 (where, x is 0-2), SO x CF 3 , O(CH 2 ) x CF 3 , SO 2 N(R 4 ) 2 , CH═NOR 4 , COCOOR 4 , COCOON(R 4 ) 2 , C 1-8 alkyls, C 3-8 cycloalkyls, CH 2 OR 4 , CH 2 (R 4 ) 2 , NR 4 SO 2 CF 3 , NO 2 , halogen, a phenyl at positions 2, 3 or 4, thienyl, furyl, pyrrole, oxazole, thiazole, N-pyrroline, triazole, tetrazole or pyridine;
R 3 is hydrogen, CF 3 , CH 2 CF 3 , C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 9 cycloalkyl-methyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, —(CH 2 ) m —R 5 (where m is 1-8), CH 2 SCH 3 or a C 4 -C 8 alkyl bonded to said nitrogen and one of its adjacent carbon atoms inclusive to form a cyclic structure;
R 4 is independently hydrogen, CF 3 , CH 2 CF 3 , C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 9 cycloalkyl-methyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluoro-butyl, —(CH 2 ) m —R 5 where m is 1-8;
R 5 is phenyl, phenyl (substituted with a CN, CF 3 , CH 2 CF 3 , C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 9 cycloalkyl-methyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl), 2-thiophenyl, 3-thiophenyl, -NR 6 CONR 6 R 7 ,or —CONR 6 R 7 ;
R 6 and R 7 are independently hydrogen, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 9 cycloalkyl-methyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl; and with the proviso that when R 1 is 2-CN or 4-CN, R 2 is H, R 3 is n-Pr and n is 1 or 3 then such compound is a pure enantiomer.
15 . The method of claim 14 wherein, in said formula (B), said R 1 is CN.
16 . The method of claim 14 wherein, in said formula (B), said R 2 is H and R 3 is n-propyl.
17 . The method of claim 14 wherein, in said formula (B), said R 1 is an —OSO 2 CF 3 .
18 . The method of claim 14 wherein, in said formula (B), said R 2 is H and R 3 is a C 1-8 alkyl.
19 . The method of claim 14 wherein, in said formula (B), said n is 2.
20 . The method of claim 14 wherein, in said formula (B), said R 1 is 3-OH, R 2 is H, R 3 is n-propyl and R 4 is a C 1-8 alkyl.
21 . The method of claim 14 wherein, in said formula (B), said n is 0.
22 . The method of claim 14 wherein said compound of formula (B) is a compound of formula (Ba):
23 . The method of claim 14 wherein said compound of formula (B) is (3S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride (uninverted CAS name) or OSU 6162 or (3S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride (Generated by ACD/Name software).
24 . The method of claim 14 wherein said compound of formula (B) is a compound of formula (Bb):
25 . The method of claim 14 wherein said compound of formula (B) is (3S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine hydrobromide (uninverted CAS name) or (3S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrobromide (Generated by ACD/Name software).
26 . The method of claim 14 wherein said compound of formula (B) is a compound of formula (Bc):
27 . The method of claim 14 wherein said compound of formula (B) is (3S)-3-[3Methylsulfonyl)phenyl]-1-propylpiperidine (2E)-2-butenedioate (1:1) (uninverted CAS name) or (S)-OSU6162.
28 . The method of claim 1 wherein said cabergoline-type compound is 1-((6-allylergolin-8β-yl) -carbony.)-1-(3-(dimethylamino)propyl)-3-ethylurea.
29 . The method of claim 1 wherein said cabergoline-type compound is cabergoline, or a pharmaceutically acceptable salt thereof.
30 . The method of claim 1 wherein said active agent is a cabergoline-type compound of formula (C),
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2003191149A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.